MYB

Across TCGA pan-cancer cohorts, MYB Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MYB data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MYB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYB expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

ESCA, UCEC, and MESO are the cancer types where MYB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.153	0.707	<.001	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.436	.010	32	view →
MESO	DFS	Median	II,III,IV	0.039	0.407	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
SKCM	DFS	Median	All	0.303	0.652	<.001	11	view →
STAD	DFS	Median	All	1.000	0.542	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MYB–ESCA (OS)

Open the ESCA breakdown →